期刊
SEMINARS IN OPHTHALMOLOGY
卷 32, 期 3, 页码 309-315出版社
TAYLOR & FRANCIS INC
DOI: 10.3109/08820538.2015.1072222
关键词
Bevacizumab; bi-weekly; neovascular age-related macular degeneration; pigment epithelial detachment; ranibizumab; refractory
资金
- Wills Eye Innovation Grant
Objective: To describe visual and anatomical outcomes following bi-weekly intravitreal ranibizumab/bevacizumab injections in eyes with refractory neovascular age-related macular degeneration (AMD) and pigment epithelial detachment (PED). Design: Retrospective, consecutive, interventional case series. Participants: Eighteen patients diagnosed with neovascular AMD that were refractory to anti-VEGF therapy and received alternating biweekly ranibizumab/bevacizumab injections were included. Methods: Patients with neovascular AMD and PED that were refractory to at least 11 monthly ranibizumab or bevacizumab injections were included in this study at a large, single retina practice. Following inclusion, patients received four bi-weekly alternating ranibizumab/bevacizumab intravitreal injections. After completing a course of four bi-weekly injections, patients were treated with variable regimens of intravitreal anti-vascular endothelial growth factor (VEGF) therapy. The primary outcomes of the study included change in visual acuity (VA) and central foveal thickness (CFT) at eight weeks follow-up. Results: Study eyes had previously received a mean of 22 intravitreal anti-VEGF injections. At enrollment, mean VA was 20/95 and mean CFT was 455 mu m. After four bi-weekly anti-VEGF injections, mean VA improved to 20/65 (p<0.001), and mean CFT decreased to 387 mu m (p=0.029). In patients with PED, there was a mean 27.9% reduction in height (p=0.046) at eight weeks' follow-up. Conclusions: Four injections of bi-weekly alternating ranibizumab/bevacizumab improved visual acuity and reduced macular thickness in a number of patients with refractory neovascular AMD and PED.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据